Clinical and Radiographic Success of MTA vs Biodentine
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age2-12
SponsorGeisinger Clinic
About this trial
The purpose of this prospective study is to compare the clinical and radiographic success of MTA and Biodentine as a medicament in vital pulp therapy in maxillary and mandibular primary molars in a pediatric population. There is limited research currently on Biodentine since it's a novel product. Biodentine is less expensive than MTA and does not cause discoloration like MTA. Biodentine may be an alternative medicament used for vital pulp therapy in primary molars.
Eligibility criteria
Qualifiers
Male or female patients ages of 2 to ≤12 years.
Bilateral symptomatic or asymptomatic vital primary molars with caries approximating or into the pulp.
Patient who need a pulpotomy and/or indirect pulp cap treatments in two or more quadrants.
Parents of patients who can provide consent in English.
Disqualifiers
Pre-operative radiographic or clinical symptoms associated with irreversible pulpitis or necrotic pulp.
Radiographs not displaying furcation region of the tooth.
Patients with cardiac conditions who need prophylaxis for infective Endocarditis.
Patients with any type of cancer in the past or present.
Trial design
Treatments tested in this trial
- Biodentine
- mineral trioxide aggregate (MTA)
Treatment groups
646 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov